Evaluation of HA Dermal Fillers in the Treatment of Pathological Facial Lipoatrophy

Exclusion Criteria

• •1. Pregnant and breastfeeding women
• •2. Subject who is deprived of their freedom by administrative or legal decision.
• •3. Subject living in a social or sanitary establishment.
• •4. Major subject who is under guardianship or who is not able to express his consent.
• •5. Subject being in an exclusion period for a previous study or with a current or recent (\<3 months) participation in another investigational study involving a drug or combined device with drug.
• •6. Subject who has scars, moles, sunburn, too many hairs, or other blemishes in the test area (face) which would interfere with the evaluation.
• •7. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results: diabetes, autoimmune pathology, cardiac pathologies, hepatic deficiency, epilepsy, porphyria (other than HIV and related HIV disease).
• •8. Subject who has a known history of severe multiple allergies, angioedema or anaphylactic shock.
• •9. Subject with a known allergy or hypersensitivity to Hyaluronic Acid or local anesthesia (Lidocaine or anesthetics of the amide type or any of the excipients)
• •10. Subject with an acute inflammatory process or active skin disease, or related conditions, such as infection, psoriasis, rosacea, acne, blotches or other pathology near or on the injection sites with the potential to interfere with the study results or increase the risk of Adverse Events at the Investigator appreciation (other than HIV and related HIV disease).
• •11. Subject with a past history of severe streptococcal disease or an active streptococcus infection.
• •12. Subject predisposed to keloid or hypertrophic scarring.
• •13. Subject with a disorder that may impact wound healing such as connective tissue or immunosuppressive disorder (other than HIV and related HIV disease).
• •14. Subject with a history of precancerous lesions/skin malignancies on the injection sites.
• •15. Subject with history of hyper- or hypo-pigmentation on the face.
• •16. Subject with a known bleeding disorder or receiving medication that will likely increase the risk of bleeding during treatment, at the Investigator appreciation.
• •17. Subject having received high dose of Lidocaine (more than 200mg) and/or high dose of anesthetics structurally related to amide-type within the past week.
• •18. Subject having received chemotherapy agents, immunosuppressive medications or systemic corticosteroids within the past 3 months.
• •19. Patient having taken high-dose aspirin, anti-inflammatories, antiplatelet, thrombolytic during the week before the injection session.
• •20. Subject having received within the past 12 months any injections including nonpermanent fillers (e.g., Hyaluronic Acid, CaHA), mesotherapy or neurotoxin near or on the cheeks and/or cheekbones and/or infraorbital hollows or plan to undergo such treatment during the study.
• •21. Subject with prior permanent implant or treatment with non-HA or non-collagen filler near or on the cheeks and/or cheekbones and/or infraorbital hollows or plan to implement these products at any time during the study.
• •22. Subject having received within the past 6 months mesotherapy, resurfacing laser, photo modulation, intense pulsed light, radio frequency, photo-rejuvenation, dermabrasion, chemical peel, or other ablative or none ablative procedures near or on cheekbones and/or infraorbital hollows.
• •23. Subject with subcutaneous retaining structure on the face (meshing, threads, gold strand etc.).
• •24. Patient having received fat grafting within the past 12 months
• •25. Other condition preventing the subject to participate the study in the Investigator's opinion: subject deemed unreliable or incapable of understanding and complying with the study assessment or unrealistic expectations of treatment results.
• •26. Subject willing to perform any aesthetic treatment on the face other than treatment planned in the protocol during the study period.
• •27. Subject who have planned an intensive exposure to sunlight or UV-rays in the 2 weeks following injection.